101. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.
- Author
-
Sabrina Greulich, Weena J Y Chen, Bujar Maxhera, Luuk J Rijzewijk, Rutger W van der Meer, Jacqueline T Jonker, Heidi Mueller, Daniella Herzfeld de Wiza, Ralf-Ruediger Floerke, Konstantinos Smiris, Hildo J Lamb, Albert de Roos, Jeroen J Bax, Johannes A Romijn, Jan W A Smit, Payam Akhyari, Artur Lichtenberg, Juergen Eckel, Michaela Diamant, and D Margriet Ouwens
- Subjects
Medicine ,Science - Abstract
CONTEXT: Adipokines are linked to the development of cardiovascular dysfunction in type 2 diabetes (DM2). In DM2-patients, circulating levels of omentin-1, an adipokine preferentially expressed in epicardial adipose tissue, are decreased. This study investigated whether omentin-1 has a cardioprotective function. METHODS: Omentin-1 levels in plasma and cardiac fat depots were determined in DM2-patients versus controls. Moreover, the relation between omentin-1 levels and cardiac function was examined in men with uncomplicated DM2. Finally, we determined whether omentin-1 could reverse the induction of cardiomyocyte dysfunction by conditioned media derived from epicardial adipose tissue from patients with DM2. RESULTS: Omentin-1 was highly expressed and secreted by epicardial adipose tissue, and reduced in DM2. Circulating omentin-1 levels were lower in DM2 versus controls, and positively correlated with the diastolic parameters early peak filling rate, early deceleration peak and early deceleration mean (all P
- Published
- 2013
- Full Text
- View/download PDF